XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal domin…
| Métrica | XRTX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -9.9% | -39.2% | +29.3% |
| ROA | -7.5% | -30.9% | +23.4% |
| Current Ratio | 28.78 | 2.73 | +26.05 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY21 | FY20 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -7.5% | — |
| ✗Flujo de caja operativo positivo | −CA$6M | −CA$728,401 |
| ✓Rentabilidad sobre activos al alza | -7.5% | -56.1% |
| ✗Caja operativa/activos supera al ROA | -27.5% | ROA -7.5% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 28.78 | 1.99 |
| ✗Sin aumentar el nº de acciones | — | — |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
XORTX Therapeutics Inc. cotiza a 1.24 USD y tiene una capitalización bursátil de $2M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud